Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 20/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19632768 | 1.00 | GRM2 (0.56) | GRM2CYP2C9CYP2C19SLC6A3SIGMAR1 | |
| SCHEMBL10322199 | 0.76 | GRM2 (0.73) | GRM2CYP2C9CYP2C19SLC6A3SIGMAR1 | |
| SCHEMBL750851 | 0.74 | GRM2 (0.77) | GRM2CYP2C9CYP2C19SLC6A3SIGMAR1 | |
| SCHEMBL19633227 | 0.74 | GRM2 (0.56) | GRM2CYP2C9CYP2C19SLC6A3SIGMAR1 | |
| SCHEMBL10321374 | 0.72 | GRM2 (0.67) | GRM2CYP2C9CYP2C19SLC6A3SIGMAR1 | |
| SCHEMBL745634 | 0.72 | GRM2 (1.00) | GRM2CYP2C9CYP2C19SLC6A3SIGMAR1 | |
| SCHEMBL19633226 | 0.72 | GRM2 (0.52) | GRM2CYP2C9CYP2C19SLC6A3SIGMAR1 | |
| SCHEMBL742212 | 0.72 | GRM2 (0.71) | GRM2 | |
| SCHEMBL747935 | 0.71 | GRM2 (0.70) | GRM2CYP2C9CYP2C19SLC6A3SIGMAR1 | |
| SCHEMBL21084285 | 0.71 | GRM2 (0.51) | GRM2CYP2C9CYP2C19SLC6A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3459948-B1 | FLUORINE-CONTAINING TRIAZOLOPYRIDINE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-11-17 | — | — | EP | claimed |
| US-20190202827-A1 | FLUORINE-CONTAINING TRIAZOLOPYRIDINE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-07-04 | — | — | US | claimed |
| EP-3459948-A1 | FLUORINE-CONTAINING TRIAZOLOPYRIDINE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) | 2019-03-27 | — | — | EP | claimed |
| EP-3459948-B1 | FLUORINE-CONTAINING TRIAZOLOPYRIDINE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-11-17 | — | — | EP | disclosed |
| US-10800776-B2 | Fluorine-containing triazolopyridine, and manufacturing method, pharmaceutical composition, and application thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-10-13 | — | — | US | disclosed |
| US-10800776-B2 | Fluorine-containing triazolopyridine, and manufacturing method, pharmaceutical composition, and application thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-10-13 | — | — | US | disclosed |
| US-20190202827-A1 | FLUORINE-CONTAINING TRIAZOLOPYRIDINE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-07-04 | — | — | US | disclosed |
| US-20190202827-A1 | FLUORINE-CONTAINING TRIAZOLOPYRIDINE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-07-04 | — | — | US | disclosed |
| EP-3459948-A1 | FLUORINE-CONTAINING TRIAZOLOPYRIDINE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) | 2019-03-27 | — | — | EP | disclosed |
| EP-3459948-A1 | FLUORINE-CONTAINING TRIAZOLOPYRIDINE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017198180-A1 | FLUORINE-CONTAINING TRIAZOLOPYRIDINE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | 中国科学院上海药物研究所 | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202827-A1 | FLUORINE-CONTAINING TRIAZOLOPYRIDINE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | GRM2, GRM1, GRIK2 | GRM2 1/4885CYP2C9 1781/4885CYP2C19 1772/4885 |
| US-10800776-B2 | Fluorine-containing triazolopyridine, and manufacturing method, pharmaceutical composition, and application thereof | GRM2, GRM1, GRIK2 | GRM2 1/4885CYP2C9 1781/4885CYP2C19 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.